Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 7Phase 1/2 5Phase 3 2Phase EARLY_PHASE1 1

Status

Terminated 3Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Completed × talimogene laherparepvec × Clear all
NCT00769704 2016-07-13

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

BioVex Limited

Phase 3 Completed
437 enrolled 19 charts
Dermatologic

Melanoma

NCT01368276 2015-12-18

An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma

BioVex Limited

Phase 3 Completed
31 enrolled 11 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡